Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study

Yavaş, Güler; Yavaş, Çağdaş; Acar, Hilal; Toy, Hatice; Yüce, Deniz; Ata, Ozlem

doi:10.1007/s00520-012-1584-7

Cited by 19 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then Image Pro-Plus 6.0 software for image analysis was used to calculate area ratio (fibrosis area/total field area) to evaluate the degree of mice pulmonary fibrosis. The extent of the alveolitis was graded on a scale of 0 (normal) to 3 (severe) [ 24 , 56 ]. For the grading of alveolitis, each group was comprised of three to five animals.…”

Section: Methodsmentioning

confidence: 99%

Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by γ-ray irradiation in mice

Zha

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Lung injury is one of the pathological features in human or animal after radiation and the main side effect for patient after lung cancer radiotherapy. The efficient protective strategy still needs to exploit and the underlying mechanisms remain to be investigated. We found that the expression and activity of matrix metalloproteinases (MMPs) significantly increased at the early stage of radiation-induced lung injury (RILI). Pretreatment with Ilomastat, a synthetic inhibitor of MMPs, decreased the expression and activity of MMPs and significantly alleviated the lung inflammation and fibrosis in the irradiated mice, as well as enhanced the survival of irradiated mice. In addition, the levels of TGF-β, IL-6, TNF-α and IL-1β in the tissues dramatically reduced in the irradiated mice pretreated with Ilomastat. Furthermore, our experiments in vitro also showed that radiation significantly increased the MMPs activity, and Ilomastat pretreatment inhibited the activity of MMPs activated by irradiation and increased the cell survival. It is the first report, to our knowledge, to demonstrate that Ilomastat is a potential effective reliever for RILI and MMPs may play important roles in the process of RILI.

show abstract

Section: Methodsmentioning

confidence: 99%

Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by γ-ray irradiation in mice

Zha

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…The group acknowledged that the follow-up may be insufficient as trial follow-up ranged from about two to seven years. The findings in these studies are supported by animal models that have identified an increase in transforming growth factor beta (TGFb) associated with tamoxifen use, which increases the rates of fibrosis in irradiated tissues [ 22 - 23 ]. However, these effects were asymptomatic and detected only on serial imaging in the case of lung fibrosis and not associated with changes in cosmetic outcome in the breast.…”

Section: Resultsmentioning

confidence: 93%

A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy

Cecchini¹,

Yu²,

Yaremko³

et al. 2016

Cureus

View full text Add to dashboard Cite

Background and objectives: For hormone-sensitive breast cancers, treatment with breast-conserving surgery, tamoxifen, or aromatase inhibitors, along with adjuvant radiation, is the mainstay of therapy. The ideal timing of hormonal and radiation treatment is not well defined, and there is a significant degree of practice variability between concurrent and sequential treatment regimes. This variability can cause confusion amongst the clinical team resulting in contradictory recommendations, loss of patient trust, and the potential for missed initiation of hormonal therapy.Methods: To address this question, a systematic review of the literature was conducted and presented to the breast cancer multidisciplinary team at the London Regional Cancer Center. A three-round modified Delphi method was used to obtain a consensus on a series of a priori determined statements.Results: With the currently available evidence, the consensus was that hormonal therapy should be given sequentially after radiation. This will limit potential overlapping adverse effects between hormonal therapy and radiation that may decrease completion of treatment. The sequential approach has not been associated with any harm in clinical outcomes, and there is some suggestion of increased toxicity with concurrent use. However, in patients at high risk of distant recurrence, they felt it would be reasonable to consider concurrent treatment to avoid any delay in therapy.Conclusion: The consensus of our institution to utilize a sequential approach will standardize the treatment decisions and reduce the risk of failing to initiate hormonal therapy. Despite the lack of level 1 evidence, the Delphi methodology did provide a high level of confidence for our group to choose the sequential approach. The consensus was developed after a review of the literature revealed that there was no clear superiority of one schedule over the other and evidence that concurrent treatment may increase adverse events.

show abstract

“…Extent of the inflammation and congestion was graded on a scale of 0 (normal) to 4 (severe) as described in Table 1. 9 Fibrosis was defined as the thickened alveolar walls with superimposed collagen. As a quantitative end point, extent of the radiation-induced fibrosis was graded on a scale of 0 (normal lung or minimal fibrous thickening) to 4 (total fibrous obliteration of Increased fibrosis with definitive damage to lung structure and formation of fibrous bands or small fibrous masses 3…”

Section: Light Microscopymentioning

confidence: 99%

Evaluation of the Effect of Changes in Dose Rate on Rat Lung Cells

Hürmüz

Kivanc

Canbolat

et al. 2014

Technol Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

show abstract

Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study

Cited by 19 publications

References 28 publications

Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by γ-ray irradiation in mice

Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by γ-ray irradiation in mice

A Single Institution Consensus on the Use of Sequential or Concurrent Hormonal Therapy for Breast Cancer Patients Receiving Radiation Therapy

Evaluation of the Effect of Changes in Dose Rate on Rat Lung Cells

Contact Info

Product

Resources

About